



ChemoTech's Animal Care Expands University Partnerships with SLU Equine Hospital in Ultuna

Scandinavian ChemoTech AB's subsidiary dedicated to Animal Care, VQ Animal Care Inc., has entered a clinical partnership with the SLU University Animal hospital, Equine clinic, in Ultuna, Sweden. Following a series of on-site training sessions and clinical introductions during the spring of 2025, SLU's Equine Surgery team, led by Dr. Dylan Gorvy BSc BVSc PhD CertES (Soft Tissue) Dipl. ECVS, has decided to integrate ChemoTech's Tumour-Specific Electroporation (TSE) therapy into their treatment offerings.

This collaboration is the result of VQ Animal Care's strategic initiative to engage with leading university veterinary teams to broaden the clinical adoption of TSE therapy. The training and introduction period at SLU included treatments both with and without general anaesthesia, further demonstrating the flexibility and patient-friendly nature of the TSE platform.

"This partnership with SLU marks another important milestone in our efforts to expand TSE therapy into top-tier academic and clinical environments," said Mohan Frick, CEO and Co-Founder of Scandinavian ChemoTech. "Working alongside a highly respected team like Dr. Gorvy's will not only help us refine our methods but also create further opportunities for advancing veterinary oncology care in Sweden and beyond."

Dr. Dylan Gorvy, Head of Equine Surgery at SLU's Equine clinic, added:

"We are always looking for innovative techniques that can improve patient outcomes and broaden our treatment options. Sarcoids and other tumours can be challenging to manage, particularly when located in areas where conventional surgery carries higher risks or longer recovery times. Having TSE therapy in our arsenal means we can treat many of these cases in a minimally invasive way, often without the need for general anaesthesia. This is a significant advantage for both the horse and the veterinary team, and I am excited to see the role TSE can play in improving equine cancer care."

This strategic partnership exemplifies ChemoTech's ongoing commitment to advancing cancer care in animals through innovative, minimally invasive technologies. It highlights our dedication to improving animal healthcare by delivering faster, less invasive therapies that reduce hospital stay duration, enhance recovery times, and increase time efficiency for veterinary teams—ultimately lowering overall costs for owners and providing a quicker return on investment for clinics.

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 12-09-2025 07:23 CET.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.